This company develops novel cancer therapies by integrating chemical biology and covalent ligand discovery platforms to address previously intractable drug targets. Their INFINI-T platform uses chimeric proteins and chemical genetics to validate target biology and guide pharmacology requirements. The CODON engine employs a diverse library of covalent fragments to discover and optimize small molecule leads matched to specific target biology.
Funding
$60M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer drug targets are considered "intractable" due to the lack of high-quality ligands and limited understanding of the pharmacological requirements for effective modulation. This presents a significant challenge in developing effective treatments for patients with cancers that rely on these targets.
Solution
Nexo Therapeutics is developing a molecule oncology platform that combines covalent ligand discovery and chemical biology to unlock a pipeline of novel cancer therapies directed against previously intractable targets. The company's approach leverages two purpose-built platforms: INFINI-T, which uses chimeric proteins and chemical genetics to validate and guide target biology and pharmacology, and CODON, a library of over 10,000 covalent fragments for ligand discovery. By integrating these platforms, Nexo aims to identify and optimize small-molecule therapies with detailed pharmacological insights, addressing the unmet need for effective treatment options. The INFINI-T platform provides insights into the depth and duration of target modulation needed to drive pharmacology, while the CODON platform uses protein structure and computation to optimize covalent hits into leads.
Target Audience
The primary target audience includes cancer patients with limited treatment options and pharmaceutical companies seeking novel cancer therapies for previously intractable targets.
Features
- INFINI-T platform: Utilizes chimeric proteins and chemical genetics to validate and guide target biology and pharmacology.
- CODON platform: Employs a library of over 10,000 covalent fragments for ligand discovery, extending beyond cysteine to address all ligandable amino acids.
- Scalable biochemical and in-cell proteomics for ligand discovery.
- Integrates protein structure and computation to optimize covalent hits into leads.
- Focuses on matching small molecule modality to target biology.